Core Viewpoint - The inclusion of药捷安康-B (02617) in the Hang Seng Composite Index is expected to enhance its visibility and liquidity in the market, with potential adjustments to the Hong Kong Stock Connect investment scope [1] Group 1: Company Developments -药捷安康-B has been included in the Hang Seng Composite Index, with the change effective from September 8, 2025, following the announcement on August 22 [1] - The company’s self-developed multi-target kinase inhibitor,替恩戈替尼 (TT-00420), has received Fast Track designation from the FDA for the treatment of metastatic castration-resistant prostate cancer [1] -替恩戈替尼 is currently in global Phase III registration trials, targeting FGFR/VEGFR, JAK, and Aurora kinases for its anti-tumor effects, showing potential efficacy in treating various solid tumors in ongoing clinical trials in the US and China [1] Group 2: Market Implications - The inclusion in the Hang Seng Composite Index may lead to an increase in the stock's market capitalization and liquidity, as it meets criteria such as market value, liquidity, and listing duration [1] - There is a possibility that药捷安康-B could be added to the Hong Kong Stock Connect, further broadening its investor base [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of June 30, 2025, with the inclusion of Jiangsu Hengrui Medicine Co., Ltd. (02617) in the Hang Seng Composite Index, effective after market close on September 5 and starting September 8 [1] - According to Huatai Securities research, Jiangsu Hengrui Medicine Co., Ltd. may be included in the Stock Connect program due to meeting various criteria including market capitalization, liquidity, and listing duration [1] Group 2 - Jiangsu Hengrui Medicine Co., Ltd. announced that its self-developed multi-target kinase inhibitor, TT-00420, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer [1] - The company stated that TT-00420 is currently in global Phase III registration trials, targeting FGFR/VEGFR, JAK, and Aurora kinases to exert anti-tumor effects, with clinical trials in the U.S. and China showing potential efficacy in treating various solid tumors [1]

格隆汇8月13日丨药捷安康-B(02617.HK)宣布，谨定于2025年8月25日(星期一)举行董事会会议，藉以(其 中包括)(i)考虑及批准公司及其附属公司截至2025年6月30日止六个月的未经审核综合中期业绩及其发 布；(ii)考虑宣派及派付中期股息(如有)；以及(iii)处理任何其他事项。 ...

董事會會議召開日期 藥捷安康（南京）科技股份有限公司（「本公司」）董事會（「董事會」）茲宣佈，謹定 於2025年8月25日（星期一）舉行董事會會議，藉以（其中包括）(i)考慮及批准本 公司及其附屬公司截至2025年6月30日止六個月之未經審核綜合中期業績及其發 佈；(ii)考慮宣派及派付中期股息（如有）；以及(iii)處理任何其他事項。 承董事會命 藥捷安康（南京）科技股份有限公司 董事長兼首席執行官 吳永謙博士 香港，2025年8月13日 於本公告日期，董事會包括執行董事吳永謙博士及吳笛先生；非執行董事賈中新 女士及易華博士；及獨立非執行董事徐海音女士、鄭哲蘭女士及李書湃先生。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2617） ...

Summary of Key Points Core Viewpoint - A total of 142 stocks reached their 52-week highs as of August 12, with notable performers including Yingmei Holdings (02028), Elite Group (01775), and Fuying Global Group (01620) achieving high rates of 164.89%, 84.78%, and 40.63% respectively [1]. Stock Performance - **Top Performers**: - Yingmei Holdings (02028) closed at 0.223 with a peak of 0.249, marking a 164.89% increase [1]. - Elite Group (01775) closed at 0.350 with a peak of 0.425, reflecting an 84.78% increase [1]. - Fuying Global Group (01620) closed at 0.180, reaching its peak at 0.180, showing a 40.63% increase [1]. - **Other Notable Stocks**: - Aoya Group (02425) increased by 34.36% [1]. - Fuyiy International Holdings (01470) saw a rise of 28.30% [1]. - Huajian Medical (01931) experienced a 27.58% increase [1]. 52-Week High Rankings - The ranking of stocks that reached their 52-week highs includes: - Yingmei Holdings (02028) at 164.89% [1]. - Elite Group (01775) at 84.78% [1]. - Fuying Global Group (01620) at 40.63% [1]. 52-Week Low Rankings - The report also highlights stocks that reached their 52-week lows, with notable declines including: - Jiadeng International Group (08153) at -15.25% [4]. - Kun Group (00924) at -12.86% [4]. - Zhongjia Guoxin (00899) at -10.00% [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 本公司全體董事及全體監事均出席股東週年大會。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2617） 於2025年8月4日舉行的股東週年大會的投票表決結果 董事會欣然宣佈，所有提呈決議案已於2025年8月4日舉行的股東週年大會上獲 股東以投票方式正式通過。 茲提述藥捷安康（南京）科技股份有限公司（「本公司」）日期為2025年7月11日的股 東週年大會通告（「通告」）及通函（「通函」）。除文義另有所指外，本公告所用詞彙 與通函所界定者具有相同涵義。 董事會欣然宣佈，通告所載所有提呈決議案已於股東週年大會上獲股東以投票方 式正式通過。 於股東週年大會日期，本公司已發行股份總數為396,897,633股，其中301,666,673 股為H股，95,230,960股為非上市股份。所有股份持有人有 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 藥捷安康 (南京 )科技股份有限公司 呈交日期: 2025年8月4日 FF301 第 1 頁 共 10 頁 v 1.1.1 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02617 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,666,673 | RMB | | 1 RMB | | 301,666,673 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,666,673 | RMB | | 1 RMB | | 301,666,673 | ...

Group 1: Investment Opportunities - Vili Zhibo-B (HK02617) has launched its IPO with a subscription rate of approximately 178.91 times on the first day, indicating strong investor confidence in its prospects [1] - Aux Group has refiled its listing application with the Hong Kong Stock Exchange, aiming to enhance brand influence and expand into international markets [2] - Fourth Paradigm (HK06682) plans to place 25.9 million shares at a subscription price of HKD 50.50 per share, raising approximately HKD 1.306 billion for investment in emerging fields like AI and blockchain [3] - October Rice Field (HK09676) expects an adjusted net profit of at least HKD 283 million for the six months ending June 30, 2025, representing a growth of no less than 90% year-on-year due to product innovation and improved sales channels [4] Group 2: Market Performance - The Hang Seng Index closed at 24,498.95, down 0.08% on July 17 [5] - The Hang Seng Tech Index increased by 0.56% to 5,448.85 [5] - The National Enterprises Index fell by 0.09% to 8,853.10 [5]

Group 1 - The stock of Yaojie Ankang-B (02617) rose over 10%, reaching a new high of 30.7 HKD, which is an increase of over 130% from the IPO price of 13.15 HKD [1] - As of the report, the stock was up 8.83% at 30.2 HKD, with a trading volume of 24.18 million HKD and a market capitalization that briefly exceeded 12 billion HKD [1] - Yaojie Ankang announced that its self-developed multi-target kinase inhibitor, TT-00420, received Fast Track designation from the FDA for the treatment of metastatic castration-resistant prostate cancer [1] Group 2 - According to Frost & Sullivan, the global CCA drug market is expected to reach 2 billion USD by 2024, with a compound annual growth rate (CAGR) of 16.2% from 2019 to 2024 [2] - The market is projected to grow to 3.2 billion USD by 2027, with a CAGR of 17.1% from 2024 to 2027, and further increase to 4.6 billion USD by 2030, with a CAGR of 12.8% from 2027 to 2030 [2] - The company is a leader in the niche industry, with Tinengotinib being the first and only FGFR inhibitor entering the registration clinical stage for treating recurrent or refractory cholangiocarcinoma patients [2]

Core Insights - The FDA has granted fast track designation to Tinengotinib (TT-00420) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) [1][2] - mCRPC is a significant cause of mortality in prostate cancer patients, with global incidence projected to rise from 180,500 cases in 2019 to 209,300 cases in 2024 due to aging populations [1] - Tinengotinib is a multi-target kinase inhibitor in Phase III trials, showing potential efficacy in treating various solid tumors [1][2] Company Developments - Tinengotinib is the first and only drug with clinical efficacy evidence targeting both FGFR and JAK pathways for mCRPC [2] - In early-phase clinical trials, Tinengotinib demonstrated an overall response rate (ORR) of 46% and a disease control rate (DCR) of 85%, with over 90% of patients experiencing tumor volume reduction [2] - The successful fast track designation for Tinengotinib highlights the company's efficient clinical and regulatory execution capabilities [2]